Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 5 Breast 5 Gastrointestinal 4 Tumor-Agnostic 1 Head & Neck 1 Gynecologic 1 Genitourinary 1 Dermatologic 1

Conditions

Interventions

Specimen Handling 18 Biopsy 18 pembrolizumab 12 Magnetic Resonance Spectroscopy 12 Paclitaxel 8 X-Rays 5 Bevacizumab 5 trastuzumab deruxtecan 4 durvalumab 4 atezolizumab 4 Standard of Care 4 Fluorouracil 4 Carboplatin 4 Capecitabine 4 Blood Specimen Collection 4 nilotinib 3 ipatasertib 3 Taxes 3 Radiotherapy 3 Pemetrexed 3 Oxaliplatin 3 Nivolumab 3 Leucovorin 3 Exercise 3 Cetuximab 3 trametinib 2 olaparib 2 inavolisib 2 dostarlimab 2 copanlisib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

patritumab deruxtecan × Tumor-Agnostic × 30 days × Clear all

NCT06941272 2026-05-12

MK-9999-01C

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡